| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | PDGF-R α |
| Clinical data | |
| Trade names | Lartruvo |
| Other names | IMC-3G3, LY-3012207 |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | Intravenous infusion |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | None |
| Metabolism | Proteolytic enzymes |
| Elimination half-life | 11 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6554H10076N1736O2048S40 |
| Molar mass | 147241.21 g·mol−1 |
  (what is this?) (verify) | |
Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors. It is directed against the platelet-derived growth factor receptor alpha.[2]
It was removed from the United States and European Union markets in 2019, due to insufficient proof of its medical advantage (see below "Medical uses").
- ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
- ^ "Statement on a Nonproprietary name adopted by the USAN Council: Olaratumab" (PDF). Archived from the original (PDF) on 15 August 2016. Retrieved 18 March 2010.